SCYNEXIS (NASDAQ:SCYX) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of SCYNEXIS (NASDAQ:SCYX) from a buy rating to a sell rating in a research note published on Saturday.

Separately, reiterated a “buy” rating on shares of SCYNEXIS in a research report on Monday, March 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.00.

SCYNEXIS Trading Down 4.0%

SCYNEXIS stock opened at $0.74 on Friday. The stock has a market cap of $33.05 million, a PE ratio of -1.54 and a beta of 1.12. The stock has a 50-day moving average price of $0.92 and a 200 day moving average price of $0.77. SCYNEXIS has a 52 week low of $0.57 and a 52 week high of $1.31.

SCYNEXIS (NASDAQ:SCYX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.32). SCYNEXIS had a negative return on equity of 57.16% and a negative net margin of 41.79%. On average, equities analysts predict that SCYNEXIS will post -0.2 EPS for the current year.

Institutional Trading of SCYNEXIS

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in SCYNEXIS in the 2nd quarter valued at about $27,000. Sequoia Financial Advisors LLC purchased a new stake in SCYNEXIS in the 3rd quarter valued at about $41,000. GSA Capital Partners LLP grew its holdings in SCYNEXIS by 95.2% in the 3rd quarter. GSA Capital Partners LLP now owns 104,423 shares of the company’s stock valued at $80,000 after buying an additional 50,916 shares during the period. Renaissance Technologies LLC grew its holdings in SCYNEXIS by 27.6% in the 1st quarter. Renaissance Technologies LLC now owns 224,640 shares of the company’s stock valued at $206,000 after buying an additional 48,640 shares during the period. Finally, Bridgeway Capital Management LLC grew its holdings in SCYNEXIS by 4.2% in the 2nd quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock valued at $248,000 after buying an additional 14,689 shares during the period. Hedge funds and other institutional investors own 54.37% of the company’s stock.

SCYNEXIS Company Profile

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.